IGF-1 DES

IGF-1 DES (IGF-1 DES(1-3)) is a truncated IGF-1 variant lacking the first three N-terminal amino acids (Gly-Pro-Glu), resulting in substantially reduced binding to IGF-binding proteins (IGFBPs) and enhanced local anabolic potency. It has a very short circulating half-life and primary action at the injection site, distinguishing it from the long-acting IGF-1 LR3. IGF-1 DES is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.

What is IGF-1 DES and how does the truncated IGF-1 mechanism work?

IGF-1 DES is native human IGF-1 with the first three N-terminal amino acids (Gly-Pro-Glu) removed, leaving a 67-amino-acid peptide that has substantially reduced affinity for IGF-binding proteins (IGFBPs) but retains full IGF-1 receptor activation. Deleting that N-terminal tripeptide is the documented structural reason IGF-1 DES binds IGF-binding proteins weakly — the same functional goal that IGF-1 LR3 reaches by the opposite route (adding an N-terminal extension plus an Arg³ substitution rather than removing residues). The two are distinct molecules, not interchangeable: IGF-1 DES is shorter than native IGF-1, while IGF-1 LR3 is larger (about 9,111 Da). retains full IGF-1 receptor activation IGFBPs normally bind ~99% of circulating IGF-1 Because IGFBPs normally bind ~99% of circulating IGF-1 and modulate its bioavailability, removing IGFBP affinity makes the DES variant more readily available at receptor sites — but only locally and briefly, as systemic clearance is rapid. Half-life is short (minutes to a few hours).

Evidence level: preclinical extensive (cell culture, rodent muscle models); no published human clinical trials

What does the research show for IGF-1 DES?

Preclinical studies have demonstrated potent local anabolic effects on muscle protein synthesis and satellite cell activation, with IGF-1 DES showing 2–10x greater potency than native IGF-1 in some cell culture systems. The effect profile is primarily local — short systemic half-life means injected DES acts at and near the injection site rather than producing whole-body IGF-1 elevation. No published human clinical trial data exists as of August 2026.

Evidence level: preclinical (cell culture and rodent); no human clinical trials

How does IGF-1 DES compare to IGF-1 LR3 and native IGF-1?

IGF-1 DES, IGF-1 LR3, and native IGF-1 (mecasermin) all activate IGF-1 receptors but with substantially different pharmacokinetics and use cases. DES is local-acting and short-duration; LR3 is systemic and long-acting; mecasermin is the approved native form.

What are the documented side effects of IGF-1 DES?

The local-action profile makes systemic side effects less prominent than with IGF-1 LR3 or native IGF-1 at equivalent doses — sustained systemic IGF-1 elevation is minimal because of rapid clearance. Injection-site reactions are the most common reported effect. Hypoglycemia risk is lower than with IGF-1 LR3 due to the shorter systemic exposure. Long-term safety in humans at sustained research-use dosing is unestablished.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of IGF-1 DES?

IGF-1 DES is not approved for any medical indication anywhere in the world as of August 2026. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency, but the truncated DES variant has no approval. IGF-1 DES is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.

Source: INCRELEX (mecasermin) injection — US Prescribing Information, Ipsen (labeler), via FDA (Drugs@FDA)

Why does IGF-1 DES vendor verification matter?

IGF-1 DES is a 67-amino-acid peptide — substantially larger than most GH-axis peptides — making synthesis quality control variable and endotoxin testing critical. The structural distinction (3 amino acids removed from native IGF-1) requires mass spectrometry identity confirmation to verify versus native IGF-1 or other IGF-1 analogs. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify IGF-1 DES vendors?

Peptigrity collects independent third-party Certificates of Analysis for IGF-1 DES from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. HPLC purity and mass-spectrometry identity confirmation are the key checks — a valid result must distinguish des(1-3) IGF-1 from native IGF-1 and from IGF-1 LR3 by mass. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

How does IGF-1 DES differ from IGF-1 LR3?

IGF-1 DES has a short half-life and primarily local effects at the injection site; IGF-1 LR3 has broader systemic activity from its reduced IGF-binding-protein affinity. IGF-1 LR3's commonly quoted "20–30 hour" half-life is vendor-sourced and is not established in published human pharmacokinetic data. Researchers use DES for site-specific anabolic effects and LR3 for sustained systemic IGF-1R activation. They are not interchangeable.

Is IGF-1 DES legal to purchase?

IGF-1 DES is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

Will IGF-1 DES be FDA-approved?

No active clinical development program for IGF-1 DES exists as of August 2026. FDA approval is unlikely without renewed development by a pharmaceutical sponsor. Native IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency.

Does IGF-1 DES carry hypoglycemia risk?

Less than IGF-1 LR3 because of the much shorter systemic half-life, but still some risk — IGF-1 receptor activation can produce insulin-like effects on glucose handling. Anyone considering use should be aware of the underlying axis biology and consult a licensed physician.

Does IGF-1 DES show up on a drug test?

Yes. IGF-1 and its analogues — which includes IGF-1 DES — are on the WADA Prohibited List under S2.3 (Growth Factors and Growth Factor Modulators), prohibited at all times. For drug-testing context, see do peptides show up on drug tests.

Source: WADA Prohibited List (current year)

Does Peptigrity recommend an IGF-1 DES dose?

No. IGF-1 DES is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. IGF-1 DES is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.